Background Clinical practice within the network is facilitated by a regional guideline and a relevant clinical guidance tool from the National Institute for Health and Clinical Excellence (NICE-149, August 2012).

Methods Prospective study from September 2012 until May 2013. 17 participating neonatal units within the network. 10 cases from each unit were included. These referred to term or preterm infants who required intravenous antibiotics for suspected or confirmed early onset sepsis with a minimum length of stay of 10 days. The data were analysed using SPSS 17.0.

Results 15 units participated. 149 babies were recruited with a mean gestational age of 32.2 weeks. 91.3% of babies received intravenous benzyl penicillin and gentamicin as first-line treatment. In 25% of cases there were prescribing issues regarding gentamicin. 19.5% of babies underwent a lumbar puncture. 17.5% of babies received antifungal agents. In 15.4% of which as treatment.

Conclusions The overall outcome was positive with prompt recognition of risk factors and initiation of treatment across all units. This unified policy promotes good quality of care. However, the percentage of prescribing issues regarding gentamicin was worryingly high. Hence, further studies and review of literature are required to evaluate the efficiency of our practice and to establish alternative choice of antibiotics.

Abstract PS-218

DEVELOPING A SAFER DOSING REGIMEN OF AMIKACIN IN PRETERM INFANTS

Background and aims Aminoglycosides with penicillin are commonly used first line antimicrobials of choice to target early onset sepsis organisms (1). The concern about emergence of gentamicin resistant gram-negative organism has led neonatal units to switch to Amikacin (2). The current British National formulary (BNFc) recommends a dose of 15 mg/kg/day even for preterm infants. The ideal dose of amikacin for use in preterm infants is not clearly defined. The aim of this study was to compare amikacin blood levels in preterm infants less than 32 weeks gestation receiving two dosage regimens.

Methods During initial six-month period infants received amikacin dose of 12 mg/kg/day (group 1) and subsequently after a change to 12 mg/kg every 36 h (group 2) at the neonatal unit over a four-month period at Royal London Hospital. Data was collected from the neonatal database, hospital records and drug chart. Study was approved by Clinical effectiveness unit and Chi-square test used for analysis (SPSS v22).

Results Conclusions Most preterm infants even on a lower dose of amikacin than currently recommended by BNFc develop a high

<table>
<thead>
<tr>
<th>Abstract PS-218 Table 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group 1 (amikacin 12mg/kg/day)</strong></td>
</tr>
<tr>
<td><strong>N</strong></td>
</tr>
<tr>
<td>No of babies with high trough amikacin levels (%)</td>
</tr>
<tr>
<td>Mean gestation in weeks (SD)</td>
</tr>
<tr>
<td>Mean Birth weight in grams (SD)</td>
</tr>
<tr>
<td>Mean Creatinine (range) in micromol/l</td>
</tr>
</tbody>
</table>

*p = 0.001.

The proportion of babies with high trough amikacin levels was significantly reduced after changing the dose from 24 hourly to 36 hourly.
thorugh level. There was a significant reduction in the number of babies with high trough amikacin levels after the dose was changed from 12 mg/kg/day to 12 mg/kg every 36 hours. We recommend this dose for use in infants less than 32 weeks gestation with continued monitoring of amikacin levels.

REFERENCES
1 Vergnano et al. Neonatal infections in England: the NeoniN surveillance network. AEC 2011

PS-219 PREDICTORS OF CLINICAL AND MICROBIOLOGICAL TREATMENT FAILURE IN NEONATAL BACTEREMIA
1 FY Hsu, 2MH Tsai, 3SM Chu, 1YC Huang, 2T Ming Hong. Pediatrics, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; 3Pediatrics, Yulun Chang Gung Memorial Hospital, Yulun, Taiwan
10.1136/archdischild-2014-307384.518

Aims To identify independent predictors of clinical and microbiological treatment failure and develop a predictive model in neonates with bloodstream infections (BSIs).

Methods A total of 1078 episodes of BSI occurred in 793 neonates in a tertiary-level neonatal intensive care unit (NICU) between 2004 and 2012 were enrolled. Patient demographics, underlying chronic comorbidities, clinical features, antimicrobial susceptibilities of microorganisms causing NI in neonates with bloodstream infections (BSIs).

Results Of 328 infants, 49.1% were preterm. Thirty-five nosocomial infections occurred in 19 (6.4%) patients. Incidence density was 6.8/1000 patient-days. Attract rate per patient was 1.84. Two infants (10.5%) succumbed to death, one with a liver abscess due to Staphylococcus epidermidis, other with Candida albicans sepsis. Ventilator associated-pneumonia (VAP) rate (n = 4) 2.3/1000, sepsis rate (n = 19) 5.7/1000, UTI rate (n = 10) 1.5/1000, wound infection rate (n = 1) 0.1/1000, catheter infection rate (n = 2) 4/1000 and meningitis rate were (n = 1) 0.1/1000. Of 35 nosocomial agents 22 (62.8%) were gram negative (10 Klebsiella spp, 4 Enterobacter, 3 Acinetobacter, 3 E. coli, 2 Pseudomonas), 10 (28.5%) were gram positive and 3 (8.6%) were Candida spp. All gram negatives were resistant to cephalosporins. Thirty-one percent of gram negative bacteria were resistant to carbapenems. Carbapenem-resistant gram negative agents were mainly Acinetobacter baumanii complex, Pseudomonas aeruginosa and Enterobacter cloacae complex. All bacteria were susceptible to colistine.

Conclusion ESBL positive and carbapenem-resistant gram negative bacteria are threats for NICU. It is of vital importance to implement reasonable antibiotic strategies and to propagate standard infection control measures.

PS-221 LOWER MATERNAL/NEONATAL VITAMIN D LEVELS ARE ASSOCIATED WITH INCREASED RISK OF EARLY ONSET NEONATAL SEPSIS IN TERM INFANTS
1M Cetinkaya, 2E Cekmez, 3G Buyukkale, 1E Enerter-Ercan, 2E Demir, 1T Tunc, 2F Aydin, 2G Aydemir. Neonatology, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey; 3Neonatology, Gulhane Military Medical Academy, Istanbul, Turkey
1Neonatology, Gulhane Military Medical Academy, Ankara, Turkey; 2Biochemistry, Gulhane Military Medical Academy, Ankara, Turkey
10.1136/archdischild-2014-307384.520

Background and aims Besides its well known role in bone metabolism, vitamin D also has immune modulatory effects. Although the link between vitamin D deficiency and various infections has been reported, no study has evaluated the effect of vitamin D levels on neonatal sepsis. The aim of this study was to evaluate the effect of vitamin D levels on early-onset sepsis (EOS) in term infants. The association between the severity of vitamin D deficiency and EOS was also investigated.

Methods Fifty term infants with clinical and laboratory findings of EOS (Study group) and 50 healthy infants with no signs of clinical and laboratory infection (Control group) were enrolled. Infants with high probable sepsis consisted the Study group and the healthy infants with no signs of clinical and laboratory infection were associated with the Control group. Blood for neonatal and maternal vitamin D levels were obtained from all infants and their mothers at the postpartum period at the time of hospital admission.

Results Both maternal and neonatal 25-hydroxyvitamin D (25-OH)D levels in the Study group were significantly lower compared with those of the Control group (p < 0.001). A positive correlation was detected between maternal and neonatal 25-OH D levels. Both maternal and neonatal 25-OH D levels were significantly higher in summer and with regular vitamin D supplementation during pregnancy. Severe vitamin D deficiency was significantly more common in the sepsis group.

PS-220 NOSOCOMIAL INFECTIONS DUE TO MULTIDRUG-RESISTANT MICROORGANISMS IN NEONATES
1Y Coskun, 2U Demirel, 3M Cengiz, 4M Akman, 5Y Akman. Pediatrics, Bahcesehir University School of Medicine, Istanbul, Turkey; 2Pediatrics, Yakaak Kadiri Dogum Ve Cevik Hastaliklari Hastanesi, Istanbul, Turkey; 3Infectious Disease, Goztepe Medipark Hospital, Istanbul, Turkey; 4Pediatric Surgery, Bahcesehir University School of Medicine, Istanbul, Turkey
10.1136/archdischild-2014-307384.519

Aim We aimed to evaluate nosocomial infection (NI) rate and antimicrobial susceptibilities of microorganisms causing NI in our Neonatal Intensive Care Unit (NICU).

Material and method NI affecting infants admitted to NICU of Bahcesehir University Goztepe Medicalpark Hospital between January 2012 and December 2012 were assessed using Centre For Disease Control And Prevention (CDC) criteria. Only culture-positive infants were enrolled.

Results Of 328 infants, 49.1% were preterm. Thirty-five nosocomial infections occurred in 19 (6.4%) patients. Incidence density was 6.8/1000 patient-days. Attract rate per patient was 1.84. Two infants (10.5%) succumbed to death, one with a liver abscess due to Staphylococcus epidermidis, other with Candida albicans sepsis. Ventilator associated-pneumonia (VAP) rate (n = 4) 2.3/1000, sepsis rate (n = 19) 5.7/1000, UTI rate (n = 10) 1.5/1000, wound infection rate (n = 1) 0.1/1000, catheter infection rate (n = 2) 4/1000 and meningitis rate were (n = 1) 0.1/1000. Of 35 nosocomial agents 22 (62.8%) were gram negative (10 Klebsiella spp, 4 Enterobacter, 3 Acinetobacter, 3 E. coli, 2 Pseudomonas), 10 (28.5%) were gram positive and 3 (8.6%) were Candida spp. All gram negatives were resistant to cephalosporins. Thirty-one percent of gram negative bacteria were resistant to carbapenems. Carbapenem-resistant gram negative agents were namely Acinetobacter baumanii complex, Pseudomonas aeruginosa and Enterobacter cloacae complex. All bacteria were susceptible to colistine.

Conclusion ESBL positive and carbapenem-resistant gram negative bacteria are threats for NICU. It is of vital importance to implement reasonable antibiotic strategies and to propagate standard infection control measures.

Poster symposium